Skip to content
Disclosery

Rosalind Advisors, Inc.

Follow

13F filer, CIK 1622627, TORONTO, Ontario, Canada

Rosalind Advisors, Inc. reported $248,888,076 across 38 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-14. Its ten largest share positions make up 67.25% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001622627-26-000015

Period
2026-03-31
Reported value
$249M
Holdings
38
Top 10 weight
67.25%
New
12
Sold out
16

Part of the filer group Rosalind Advisors, Inc.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PCVXnew+290,000$16.9M
VORnew+700,000$12.5M
CLDXnew+330,000$10.5M
BCRXnew+923,057$8.79M
XERSadded+1,120,000$6.5M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
REPLexited-1,410,497-$13.7M
ATYRexited-1,039,080-$13.6M
CGONreduced-200,000-$13.5M
CYTKexited-195,045-$12.4M
MIND MEDICINE MINDMED INCexited-750,000-$10M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001622627-26-000015, largest first. % of portfolio is the value over $244,077,131, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
DCTHDELCATH SYS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,650,389 shares; 2024Q4: 2,650,389 shares; 2025Q1: 2,900,389 shares; 2025Q2: 3,300,389 shares; 2025Q3: 3,300,389 shares; 2025Q4: 3,300,389 shares; 2026Q1: 3,300,389 shares 3,300,389$30.6M12.55%02026-10-13, Form 4: converted 3,627 shares on 2026-10-13 Timeline
XERSXERIS BIOPHARMA HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 3,104,995 shares; 2024Q4: 3,104,995 shares; 2025Q1: 2,495,986 shares; 2025Q2: 2,155,594 shares; 2025Q3: 1,795,766 shares; 2025Q4: 2,111,700 shares; 2026Q1: 3,231,700 shares 3,231,700$18.7M7.68%+1,120,000Timeline
FENCFENNEC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,259,876 shares; 2025Q1: 1,782,844 shares; 2025Q2: 2,045,644 shares; 2025Q3: 2,076,840 shares; 2025Q4: 2,613,508 shares; 2026Q1: 2,908,201 shares 2,908,201$17.9M7.33%+294,693Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,654,944 shares; 2025Q1: 2,654,944 shares; 2025Q2: 2,654,944 shares; 2025Q3: 4,000,000 shares; 2025Q4: 3,403,721 shares; 2026Q1: 3,203,721 shares 3,203,721$17.5M7.17%-200,000Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 290,000 shares 290,000$16.9M6.9%newTimeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 650,000 shares; 2025Q4: 690,000 shares; 2026Q1: 1,036,737 shares 1,036,737$13.4M5.48%+346,737Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,544,607 shares; 2025Q4: 2,605,920 shares; 2026Q1: 3,214,766 shares 3,214,766$13.3M5.44%+608,846Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 700,000 shares 700,000$12.5M5.12%newTimeline
MDWDMEDIWOUND LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 628,050 shares; 2024Q4: 628,050 shares; 2025Q1: 506,893 shares; 2025Q2: 407,061 shares; 2025Q3: 749,054 shares; 2025Q4: 749,054 shares; 2026Q1: 749,054 shares 749,054$12.1M4.94%0Timeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 900,000 shares; 2025Q1: 2,644,517 shares; 2025Q2: 2,043,563 shares; 2025Q3: 1,929,563 shares; 2025Q4: 1,788,475 shares; 2026Q1: 2,138,475 shares 2,138,475$11.3M4.64%+350,000Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 330,000 shares 330,000$10.5M4.29%newTimeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 923,057 shares 923,057$8.79M3.6%newTimeline
HELPCYBIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 810,918 shares; 2025Q1: 810,918 shares; 2025Q2: 810,918 shares; 2025Q3: 1,500,000 shares; 2025Q4: 1,657,540 shares; 2026Q1: 1,531,814 shares 1,531,814$7.35M3.01%-125,726Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 192,974 shares; 2025Q3: 300,000 shares; 2025Q4: 300,000 shares; 2026Q1: 100,000 shares 100,000$6.77M2.77%-200,000Timeline
NSPRINSPIREMD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,514,046 shares; 2024Q4: 2,495,783 shares; 2025Q1: 2,274,990 shares; 2025Q2: 2,289,099 shares; 2025Q3: 3,905,743 shares; 2025Q4: 3,905,743 shares; 2026Q1: 3,905,743 shares 3,905,743$6.37M2.61%0Timeline
AVIRATEA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,171,855 shares 1,171,855$6.3M2.58%newTimeline
PROFPROFOUND MED CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 485,973 shares; 2024Q4: 692,185 shares; 2025Q1: 692,185 shares; 2025Q2: 692,185 shares; 2025Q3: 692,185 shares; 2025Q4: 1,068,955 shares; 2026Q1: 828,118 shares 828,118$5.37M2.2%-240,837Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 595,000 shares; 2025Q2: 700,000 shares; 2025Q3: 600,000 shares; 2025Q4: 450,000 shares; 2026Q1: 250,401 shares 250,401$4.9M2.01%-199,599Timeline
PYPDPOLYPID LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 679,168 shares; 2024Q4: 1,018,021 shares; 2025Q1: 1,018,021 shares; 2025Q2: 975,462 shares; 2025Q3: 918,668 shares; 2025Q4: 696,556 shares; 2026Q1: 597,926 shares 597,926$2.62M1.07%-98,630Timeline
MYOMYOMO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 3,021,391 shares; 2024Q4: 2,998,945 shares; 2025Q1: 2,703,661 shares; 2025Q2: 3,595,788 shares; 2025Q3: 3,790,788 shares; 2025Q4: 3,839,772 shares; 2026Q1: 3,847,272 shares 3,847,272$2.6M1.06%+7,500Timeline
TLPHTALPHERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 758,966 shares; 2024Q4: 613,939 shares; 2025Q1: 2,003,939 shares; 2025Q2: 2,003,939 shares; 2025Q3: 4,385,757 shares; 2025Q4: 3,579,273 shares; 2026Q1: 3,353,916 shares 3,353,916$2.51M1.03%-225,357Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 500,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,107,994 shares 1,107,994$2.46M1.01%newTimeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 125,000 shares 125,000$2.36M0.97%newTimeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 730,488 shares; 2026Q1: 443,763 shares 443,763$1.84M0.75%-286,725Timeline
LPCNLIPOCINE INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 221,616 shares 221,616$1.77M0.73%newTimeline
NRXSNEURAXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 286,138 shares; 2026Q1: 286,138 shares 286,138$1.69M0.69%0Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 75,000 shares 75,000$1.12M0.46%newTimeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 200,000 shares 200,000$1.11M0.45%newTimeline
AQSTAQUESTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 250,000 shares 250,000$1.04M0.43%newTimeline
BFRIBIOFRONTERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 495,490 shares; 2024Q4: 811,918 shares; 2025Q1: 644,393 shares; 2025Q2: 976,448 shares; 2025Q3: 1,140,764 shares; 2025Q4: 1,140,764 shares; 2026Q1: 1,163,962 shares 1,163,962$942K0.39%+23,198Timeline
KURAKURA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 100,000 shares; 2025Q2: 100,000 shares; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares; 2026Q1: 100,000 shares 100,000$813K0.33%0Timeline
RGNTREGENTIS BIOMATERIALS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 251,510 shares; 2026Q1: 251,510 shares 251,510$768K0.31%0Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
REPLIMUNE GROUP INCREPLIMUNE GROUP INC CALLcall1,275,600$2.75M+1,044,700
INVESCO QQQ TRINVESCO QQQ TR PUTput250,000$1.05M-200,000
STATE STR SPDR S&P 500 ETF TSTATE STR SPDR S&P 500 ETF T PUTput125,000$958K-385,000
VIRIDIAN THERAPEUTICS INCVIRIDIAN THERAPEUTICS INC PUTput263,600$52.7Knew
UNIQURE NVUNIQURE NV CALLcall295,800$0+195,800
ARRIVENT BIOPHARMA INCARRIVENT BIOPHARMA INC COMcall108,900$0+1,000

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
REPLREPLIMUNE GROUP INC1,410,497$13.7Mshares
ATYRATYR PHARMA INC1,039,080$13.6Mshares
CYTKCYTOKINETICS INC195,045$12.4Mshares
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INC750,000$10Mshares
OCULOCULAR THERAPEUTIX INC400,000$4.86Mshares
AVBPARRIVENT BIOPHARMA INC215,871$4.34Mshares
ANAVEX LIFE SCIENCES CORPANAVEX LIFE SCIENCES CORP1,168,600$1.88Mput
SPDR SERIES TRUSTSPDR SERIES TRUST1,937,600$1.35Mput
TRVITREVI THERAPEUTICS INC100,000$1.25Mshares
ISHARES TRISHARES TR200,000$1.11Mput
GUTSFRACTYL HEALTH INC385,731$849Kshares
VERASTEM INCVERASTEM INC268,600$160Kcall
VIKING THERAPEUTICS INCVIKING THERAPEUTICS INC100,000$2Kcall
REZOLUTE INCREZOLUTE INC263,100$0call
REPLIMUNE GROUP INCREPLIMUNE GROUP INC264,700$0put
VISTAGEN THERAPEUTICS INCVISTAGEN THERAPEUTICS INC493,400$0call

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001622627-26-000015 base2026-05-14acceptance time not in the bulk data set